Visco, C, Tzankov, A, Xu-Monette, Z Y, Miranda, R N, Tai, Y C, Li, Y, Liu, W M, d'Amore, E S G, Li, Y, Montes-Moreno, S, Dybkær, K, Chiu, A, Orazi, A, Zu, Y, Bhagat, G, Wang, H Y, Dunphy, C H, His, E D, Zhao, X F, Choi, W W L, Zhao, X, Han van Krieken, J, Huang, Q, Ai, W, O'Neill, S, Ponzoni, M, Ferreri, A J M, Kahl, B S, Winter, J N, Go, R S, Dirnhofer, S, Piris, M A, Møller, M B, Wu, L, Medeiros, L J & Young, K H 2013, ' Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status : A report from an international DLBCL rituximab-CHOP consortium program study ', Haematologica, vol. 98, no. 2, pp. 255-263 . https://doi.org/10.3324/haematol.2012.066209 Visco, C, Tzankov, A, Xu-Monette, Z Y, Miranda, R N, Tai, Y C, Li, Y, Liu, W-M, d'Amore, E S G, Li, Y, Montes-Moreno, S, Dybkaer, K, Chiu, A, Orazi, A, Zu, Y, Bhagat, G, Wang, H-Y, Dunphy, C H, O' Neill, S, Hsi, E D, Zhao, X F, Choi, W W L, Zhao, X, van Krieken, J H, Huang, Q, Ai, W, Ponzoni, M A, Ferreri, A J M, Kahl, B S, Winter, J N, Go, R S, Dirnhofer, S, Piris, M A, Møller, M B, Wu, L, Medeiros, L J & Young, K H 2012, ' Patients with diffuse large B cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status : a report from an International DLBCL rituximab-CHOP Consortium Program Study ', Haematologica . https://doi.org/10.3324/haematol.2012.066209 Haematologica, 98, 255-63 Haematologica, 98, 2, pp. 255-63
Xu-Monette, Z Y, Wu, L, Visco, C, Tai, Y C, Tzankov, A, Liu, W, Montes-Moreno, S, Dybkaer, K, Chiu, A, Orazi, A, Zu, Y, Bhagat, G, Richards, K L, Hsi, E D, Zhao, X F, Choi, W W L, Zhao, X, van Krieken, J H, Huang, Q, Huh, J, Ai, W, Ponzoni, M, Ferreri, A J M, Zhou, F, Kahl, B S, Winter, J N, Xu, W, Li, J, Go, R S, Li, Y, Piris, M A, Møller, M B, Miranda, R N, Abruzzo, L V, Medeiros, L J & Young, K H 2012, ' Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP : report from an International DLBCL Rituximab-CHOP Consortium Program Study ', Blood, vol. 120, no. 19, pp. 3986-96 . https://doi.org/10.1182/blood-2012-05-433334 Blood, 120, 3986-96 Blood, 120, 19, pp. 3986-96 Xu-Monette, Z Y, Wu, L, Visco, C, Tai, Y C, Tzankov, A, Liu, W-M, Montes-Moreno, S, Dybkær, K, Chiu, A, Orazi, A, Zu, Y, Bhagat, G, Richards, K L, Hsi, E D, Zhao, X F, Choi, W W, Zhao, X, van Krieken, J H, Huang, Q, Huh, J, Ai, W, Ponzoni, M A, Ferreri, A J, Zhou, F, Kahl, B S, Winter, J N, Xu, W, Li, J, Go, R S, Li, Y, Piris, M A, Møller, M B, Miranda, R N, Abruzzo, L V, Medeiros, L J & Young, K H 2012, ' Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with rituximab-CHOP : a report from an International DLBCL Rituximab-CHOP Consortium Program study ', Blood, vol. 120, no. 19, pp. 3986-3996 . https://doi.org/10.1182/blood-2012-05-433334